{
“title”: “=FDA Clears Cerevel’s Schizophrenia Drug Trial”,
“content”: “=![\"FDA](\"https://clinicaltrialshub.com/wp-content/uploads/2025/10/GettyImages-1665778558_1-2.webp\")
\n
Cerevel Therapeutics has received FDA clearance to begin a Phase 1 clinical trial for its new schizophrenia drug candidate, CVL-874. This investigational therapy is designed to target specific dopamine receptors in the brain, offering a potential alternative to current antipsychotic treatments.
CVL-874 works by acting as a positive allosteric modulator of the D1/D5 dopamine receptors. These receptors play a central role in regulating cognitive function and behavior. Unlike many current medications which broadly block dopamine activity, CVL-874 aims to enhance dopamine signaling more selectively. According to Cerevel, this could result in fewer side effects and improved cognitive outcomes for patients with schizophrenia.
This Phase 1 study will assess safety, tolerability and pharmacokinetics in healthy volunteers. It is the first step in clinical development before evaluating the drug’s effects in patients.
Cerevel was launched in 2018 through a partnership between Bain Capital and Pfizer. Its focus is on developing new treatments for neuroscience conditions. In addition to schizophrenia, the company is also exploring therapies for Parkinson’s disease, epilepsy and other central nervous system disorders.
“,
“status”: “draft”,
“categories”: “=1”,
“featured_media”: “=1482”
}
